Filtered By:
Condition: Atrial Fibrillation
Therapy: Cardiac Resynchronization Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 92 results found since Jan 2013.

Effects of remote monitoring of cardiac implantable electronic devices after stroke or transient ischemic attack
Conclusion We found that remote monitoring as compared with conventional in-hospital visits may contribute to a better outcome in CIED recipients who had suffered from an ischemic cerebral event.
Source: Journal of Cardiovascular Medicine - August 1, 2019 Category: Cardiology Tags: Research articles: Telemonitoring Source Type: research

Atrial Fibrillation and Ventricular Arrhythmias: Sex Differences in Electrophysiology, Epidemiology, Clinical Presentation, and Clinical Outcomes.
Abstract Sex-specific differences in the epidemiology, pathophysiology, clinical presentation, clinical treatment, and clinical outcomes of atrial fibrillation (AF), sustained ventricular arrhythmias, and sudden cardiac death are recognized. Sex hormones cause differences in cardiac electrophysiological parameters between men and women that may affect the risk for arrhythmias. The incidence and prevalence of AF is lower in women than in men. However, because women live longer and AF prevalence increases with age, the absolute number of women with AF exceeds that of men. Women with AF are more symptomatic, present ...
Source: Circulation - February 6, 2017 Category: Cardiology Authors: Gillis AM Tags: Circulation Source Type: research

ESC 2017 Roundup: Biotronik touts lowered mortality for AF patients treated with cath ablation
Biotronik today released results from the Castle-AF study exploring the use of catheter ablation to treat heart failure patients with atrial fibrillation, touting a 38% composite reduction in all-cause mortality and hospitalization for worsening heart failure. The 398-patient, 33-site study compared the results of catheter ablation treatment for AF in heart failure patients using implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators to standard-of-care pharmacological therapy, the company said. Biotronik touted it as the largest study of its kind to date. Results indicated a 47% reduc...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials Biotronik Medtronic Source Type: news

Device-Detected Atrial Fibrillation: Evidencing the Knowledge Gap.
Abstract Stroke is a devastating complication of atrial fibrillation (AF) the odds of which can be reduced by use of oral anticoagulation based on the stroke risk score.1,2 Patients with asymptomatic clinical AF have a similar stroke risk as patients with symptomatic clinical AF.3 Thus far, electrocardiographic- (ECG) or Holter monitor-detected AF is a prerequisite before use of oral anticoagulation,1,2 because the guideline recommendations are based on studies that included only ECG- or Holter-detected AF ('clinical' AF).1,2 In the past decades increasing number of cardiac implantable electronic devices (CIED) ha...
Source: Circulation - March 16, 2019 Category: Cardiology Authors: Mulder BA, van Gelder IC, Rienstra M Tags: Circulation Source Type: research

Age-Dependence of Flow Homeostasis in the Left Ventricle
Conclusions: In average, blood spends 1 to 3 beats inside the LV with very low shear stress rates. The apical region is the most prone to blood stasis, particularly in mid-aged adults. The washout of blood in the normal LV is age-dependent due to physiological changes in the degree of apical penetration of the filling waves. Introduction Cardioembolic stroke is a major source of mortality and disability worldwide and blood stasis one of its major determinants (Adams et al., 1986). Left ventricular (LV) function has evolved to maximize mechanical efficiency and ensure organ perfusion at a low cost of energy and fill...
Source: Frontiers in Physiology - April 25, 2019 Category: Physiology Source Type: research

VVI Pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers
ConclusionIn patients without reduced LVEF or prolonged QRS duration who would be eligible for LP, DDDR and VVIR pacing demonstrated similar rates of death, stroke or heart failure hospitalization; however, VVIR pacing significantly increased the risk of AF development.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - October 21, 2020 Category: Cardiology Authors: Zak Loring, Rebecca North, Anne S. Hellkamp, Brett D. Atwater, Camille G. Frazier ‐Mills, Kevin P. Jackson, Sean D. Pokorney, Gervasio A. Lamas, Jonathan P. Piccini Tags: DEVICES Source Type: research

HRS 2016 roundup: Leadless pacers at the fore
Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), aiming to distinguish their respective leadless pacemaker offerings, presented new data last week in San Francisco at the Heart Rhythm Society’s annual meeting. St. Jude said a subset of data from the Leadless II trial showed that its Nanostim device was was successfully retrieved in 14 patients up to 3.2 years after implantation, with no serious adverse events. “We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability – even up to 3 years – is possible with the Nanostim leadless pacemak...
Source: Mass Device - May 9, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management HRS 2016 Medtronic St. Jude Medical Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 14, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Final FDA rules clarify adverse event reporting for contract manufacturers The FDA last week issued final guidance for medical device companies on the requirements for reporting adverse events that walked back much of the burde...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Device-detected atrial fibrillation in a large remote-monitored cohort: implications for anticoagulation and need for new pathways of service delivery
ConclusionsDespite being intensively managed via RM software system incorporating cues for anticoagulation, a substantial proportion of patients with increased stroke risk remained unanticoagulated after a device-detected AF episode of significant duration. These data highlight the need for improved clinical response pathways and an integrated care approach to RM.Trial registrationAustralian New Zealand Clinical Trial Registry: ACTRN12620001232921.Graphical Abstract
Source: Journal of Interventional Cardiac Electrophysiology - February 3, 2023 Category: Cardiology Source Type: research

Recent advances in management of atrial fibrillation in patients with heart failure
The objective of this review is to provide an overview of atrial fibrillation in HF, and the implications for management. Recent findings: At present there is no evidence that a rhythm control strategy may bring any long-term benefits in routine management of atrial fibrillation in HF. Recently, the procedure of pulmonary vein isolation has been shown to provide clinical and prognostic benefits in patients with atrial fibrillation and concomitant HF who remain symptomatic despite optimal medical therapy, including rate and rhythm control. A meta-analysis of patients with atrial fibrillation and symptomatic HF who had impla...
Source: Current Opinion in Cardiology - January 1, 2013 Category: Cardiology Tags: HEART FAILURE: Edited by Haissam Haddad Source Type: research

The Year in Review of Clinical Cardiac Electrophysiology
This past year saw multiple important advances in the field clinical cardiac electrophysiology. Seminal articles describing new anticoagulant drugs for stroke prevention in atrial fibrillation were published. New results that raise questions regarding the safety of dronedarone and several new promising techniques in AF ablation were described. Important articles that refine our understanding of the risk of sudden death among Wolff-Parkinson-White patients were published. In the basic and translational sciences, the application of gene therapy to the study and potential treatment of arrhythmias was described, whereas geneti...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 11, 2013 Category: Cardiology Source Type: research

Abstract 227: Prescribing Warfarin at Discharge for Heart Failure Patients without Atrial Fibrillation Findings from the Get With The Guidelines-Heart Failure Registry Poster Session II
Conclusions: Approximately 1 in 10 HF patients without AF or other documented indications are prescribed warfarin at discharge, and prescription rates vary widely across hospitals. Further research is needed to understand why anticoagulation is prescribed to patients with HF in the absence of documented indications.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Eapen, Z., Grau-Sepulveda, M., Fonarow, G., Heidenreich, P., Peterson, E., Hernandez, A. Tags: Poster Session II Source Type: research

CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy
Conclusion In CRT-D patients, pre-implant CHA2DS2-VASc score is an independent predictor of major clinical events at 30-month follow-up.
Source: Europace - December 16, 2013 Category: Cardiology Authors: Paoletti Perini, A., Bartolini, S., Pieragnoli, P., Ricciardi, G., Perrotta, L., Valleggi, A., Vergaro, G., Michelotti, F., Boggian, G., Sassone, B., Mascioli, G., Emdin, M., Padeletti, L. Tags: Pacing and resynchronization therapy Source Type: research

Biotronik launches Itrevia MRI-safe quad CRT-D in Japan
Biotronik said today that it launched its Itrevia MRI-safe quad cardiac resynchronization therapy defibrillator in Japan, part of a Japanese rollout of new devices for 2015. The device is equipped with home monitoring connectivity, as well as compatibility with up to 1.5 tesla MRI machines, the German medical device giant said. “As a producer of superior medical technologies, it is imperative for us to have a presence in the world’s leading technologies market. It also makes sense that the world’s biggest producer of ProMRI technology should have a strong presence in the country where MRI scanning is the...
Source: Mass Device - July 2, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Surgical Biotronik Source Type: news